Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
The prognosis and treatment options depend on the following:
The patient's signs and symptoms, including whether or not they have B symptoms (fever for no known reason, weight loss for no known reason, or drenching night sweats).
The stage of the cancer (the size of the cancer tumors and whether the cancer has spread to other parts of the body or lymph nodes).
Sources: stage
The type of non-Hodgkin lymphoma.
The amount of lactate dehydrogenase (LDH) in the blood.
Whether there are certain changes in the genes.
The patient’s age, sex, and general health.
Whether the lymphoma is newly diagnosed, continues to grow during treatment, or has recurred (come back).
Sources: recurred
For non-Hodgkin lymphoma during pregnancy, treatment options also depend on:
The wishes of the patient.
Which trimester of pregnancy the patient is in.
Whether the baby can be delivered early.
Some types of non-Hodgkin lymphoma spread more quickly than others do. Most non-Hodgkin lymphomas that occur during pregnancy are aggressive. Delaying treatment of aggressive lymphoma until after the baby is born may lessen the mother's chance of survival. Immediate treatment is often recommended, even during pregnancy.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For more information on the types of indolent (slow-growing) and aggressive (fast-growing) non-Hodgkin lymphoma, see the General Information section.
Sources: indolent · aggressive · General Information
Non-Hodgkin lymphoma can also be described as contiguous or noncontiguous:
Sources: contiguous · noncontiguous
Contiguous lymphomas: Lymphomas in which the lymph nodes with cancer are next to each other.
Sources: Lymphomas · lymph nodes
Noncontiguous lymphomas: Lymphomas in which the lymph nodes with cancer are not next to each other, but are on the same side of the diaphragm.
Sources: diaphragm
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
The lymphoma may come back in the lymph system or in other parts of the body. Indolent lymphoma may come back as aggressive lymphoma. Aggressive lymphoma may come back as indolent lymphoma.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
There are different types of treatment for patients with non-Hodgkin lymphoma.
Patients with non-Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating lymphomas.
Treatment for non-Hodgkin lymphoma may cause side effects.
The following types of treatment are used:
The following types of treatment are used:
Radiation therapy
Chemotherapy
Immunotherapy
Targeted therapy
Plasmapheresis
Watchful waiting
Antibiotic therapy
Surgery
Stem cell transplant
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Vaccine therapy
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Different types of treatment are available for patients with non-Hodgkin lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: non-Hodgkin lymphoma · standard · clinical trials · research study · cancer
For pregnant women with non-Hodgkin lymphoma, treatment is carefully chosen to protect the fetus. Treatment decisions are based on the mother’s wishes, the stage of the non-Hodgkin lymphoma, and the trimester of the pregnancy. The treatment plan may change as the signs and symptoms, cancer, and pregnancy change. Choosing the most appropriate cancer treatment is a decision that ideally involves the patient, family, and health care team.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Treatment will be overseen by a medical oncologist, a doctor who specializes in treating cancer, or a hematologist, a doctor who specializes in treating blood cancers. The medical oncologist may refer you to other health care providers who have experience and are experts in treating non-Hodgkin lymphoma and who specialize in certain areas of medicine. These may include the following specialists:
Sources: medical oncologist · hematologist · blood cancers · health care providers · medicine · specialists
Neurosurgeon.
Sources: Neurosurgeon
Neurologist.
Sources: Neurologist
Radiation oncologist.
Sources: Radiation oncologist
Endocrinologist.
Sources: Endocrinologist
Rehabilitation specialist.
Sources: Rehabilitation specialist
Fertility specialist.
Sources: Fertility specialist
Other oncology specialists.
Sources: oncology
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Treatment with chemotherapy, radiation therapy, or stem cell transplant for non-Hodgkin lymphoma may increase the risk of late effects.
Sources: late effects · chemotherapy · radiation therapy · stem cell transplant
Late effects of cancer treatment may include the following:
Heart problems.
Infertility (inability to have children).
Sources: Infertility
Loss of bone density.
Sources: bone density
Neuropathy (nerve damage that causes numbness or trouble walking).
Sources: Neuropathy · nerve
A second cancer, such as:
Sources: second cancer
Brain cancer.
Kidney cancer.
Sources: Kidney cancer
Bladder cancer.
Sources: Bladder cancer
Melanoma.
Sources: Melanoma
Hodgkin lymphoma.
Sources: Hodgkin lymphoma
Myelodysplastic syndrome.
Sources: Myelodysplastic syndrome
Acute myeloid leukemia.
Sources: Acute myeloid leukemia
Some late effects may be treated or controlled. It is important to talk with your doctor about the effects cancer treatment can have on you. Regular follow-up to check for late effects is important.
Sources: follow-up
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing.
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes total-body irradiation is given before a stem cell transplant.
Sources: External radiation therapy · total-body irradiation · stem cell transplant
Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor such as the heart or breast.
Sources: Proton beam radiation therapy · protons · tumor · tissue · breast
External radiation therapy is used to treat non-Hodgkin lymphoma, and may also be used as palliative therapy to relieve symptoms and improve quality of life.
Sources: palliative therapy · quality of life
For a pregnant woman with non-Hodgkin lymphoma, radiation therapy should be given after delivery, if possible, to avoid any risk to the fetus. If treatment is needed right away, the woman may decide to continue the pregnancy and receive radiation therapy. A lead shield is used to cover the pregnant woman's abdomen to help protect the fetus from radiation as much as possible.
Sources: lead shield · abdomen
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using two or more anticancer drugs. Steroid drugs may be added, to lessen inflammation and lower the body's immune response.
Sources: drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · intrathecal chemotherapy · organ · cavity · regional chemotherapy · Combination chemotherapy · Steroid drugs · inflammation · immune response
Systemic combination chemotherapy is used for the treatment of non-Hodgkin lymphoma.
Intrathecal chemotherapy may also be used in the treatment of lymphoma that first forms in the testicles or sinuses (hollow areas) around the nose, diffuse large B-cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma, and some aggressive T-cell lymphomas. It is given to lessen the chance that lymphoma cells will spread to the brain and spinal cord. This is called CNS prophylaxis.
Sources: lymphoma · testicles · sinuses · diffuse large B-cell lymphoma · Burkitt lymphoma · lymphoblastic lymphoma · aggressive · T-cell lymphomas · spinal cord · CNS prophylaxis
When a pregnant woman is treated with chemotherapy for non-Hodgkin lymphoma, the fetus cannot be protected from being exposed to chemotherapy. Some chemotherapy regimens may cause birth defects if given in the first trimester.
For more information, see Drugs Approved for Non-Hodgkin Lymphoma.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.
Sources: Immunotherapy · immune system
Immunomodulators: Lenalidomide is an immunomodulator used to treat non-Hodgkin lymphoma.
Sources: Immunomodulators · Lenalidomide
CAR T-cell therapy: The patient's T cells (a type of immune system cell) are changed so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy (such as axicabtagene ciloleucel or tisagenlecleucel) is used to treat large B-cell lymphoma that has not responded to treatment. CAR T-cell therapy is being studied to treat mantle cell lymphoma that has relapsed or not responded to treatment.
Sources: T cells · proteins · receptors · chimeric antigen receptor · infusion · blood · axicabtagene ciloleucel · tisagenlecleucel · B-cell lymphoma · responded · mantle cell lymphoma · relapsed
For more information, see Drugs Approved for Non-Hodgkin Lymphoma.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Monoclonal antibody therapy, proteasome inhibitor therapy, and kinase inhibitor therapy are types of targeted therapy used to treat non-Hodgkin lymphoma.
Sources: Monoclonal antibody · therapy · proteasome inhibitor · kinase inhibitor
Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Types of monoclonal antibodies include:
Sources: immune system · antibodies · infusion · toxins · radioactive
Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Types of monoclonal antibodies include:
Rituximab, used to treat many types of non-Hodgkin lymphoma.
Sources: Rituximab
Obinutuzumab, used to treat follicular lymphoma.
Sources: Obinutuzumab · follicular lymphoma
Mogamulizumab, used to treat certain types of relapsed or refractory T-cell lymphoma.
Sources: Mogamulizumab · relapsed · refractory · T-cell lymphoma
Tafasitamab combined with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma.
Sources: Tafasitamab
Pembrolizumab to treat primary mediastinal large B-cell lymphoma.
Sources: Pembrolizumab · primary mediastinal large B-cell lymphoma
Polatuzumab vedotin, combined with bendamustine and rituximab to treat relapsed or refractory diffuse large B-cell lymphoma.
Sources: Polatuzumab vedotin · bendamustine · diffuse large B-cell lymphoma
Brentuximab vedotin, which contains a monoclonal antibody that binds to a protein called CD30 that is found on some lymphoma cells. It also contains an anticancer drug that may help kill cancer cells.
Sources: Brentuximab vedotin · CD30
Yttrium Y 90-ibritumomab tiuxetan, an example of a radiolabeled monoclonal antibody.
Sources: Yttrium Y 90-ibritumomab tiuxetan · radiolabeled
Mosunetuzumab, which is a bispecific monoclonal antibody that helps the body's immune system recognize and kill cancer cells. It is used to treat relapsed or refractory follicular lymphoma.
Sources: Mosunetuzumab · bispecific monoclonal antibody
Proteasome inhibitor therapy: This treatment blocks the action of proteasomes in cancer cells. Proteasomes remove proteins no longer needed by the cell. When the proteasomes are blocked, the proteins build up in the cell and may cause the cancer cell to die. Bortezomib or ixazomib is used to decrease how much immunoglobulin M is in the blood after cancer treatment for lymphoplasmacytic lymphoma (Waldenström macroglobulinemia). It is also being studied to treat relapsed mantle cell lymphoma.
Sources: proteins · Bortezomib · ixazomib · immunoglobulin · lymphoplasmacytic lymphoma · relapsed · mantle cell lymphoma
Kinase inhibitor therapy: This treatment blocks certain proteins, which may help keep lymphoma cells from growing and may kill them. Kinase inhibitor therapies include:
Kinase inhibitor therapy: This treatment blocks certain proteins, which may help keep lymphoma cells from growing and may kill them. Kinase inhibitor therapies include:
Ibrutinib, acalabrutinib, and zanubrutinib, which are types of Bruton tyrosine kinase inhibitor therapy. They are used to treat mantle cell lymphoma. Ibrutinib and acalabrutinib are also used to treat lymphoplasmacytic lymphoma, and zanubrutinib is being studied to treat it.
Sources: Ibrutinib · acalabrutinib · zanubrutinib · tyrosine kinase inhibitor
Histone methyltransferase inhibitor therapy: Tazemetostat is used to treat follicular lymphoma that has come back or has not gotten better with other treatment. It is used in adults whose cancer has a certain mutation (change) in the EZH2 gene that has already been treated with at least two other anticancer therapies.
Sources: Histone methyltransferase inhibitor · Tazemetostat · mutation · EZH2 gene
B-cell lymphoma-2 (BCL-2) inhibitor therapy: Venetoclax may be used to treat mantle cell lymphoma. It blocks the action of a protein called BCL-2 and may help kill cancer cells.
Sources: B-cell lymphoma-2 · Venetoclax
For more information, see Drugs Approved for Non-Hodgkin Lymphoma.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
If the blood becomes thick with extra antibody proteins and affects circulation, plasmapheresis is done to remove extra plasma and antibody proteins from the blood. In this procedure, blood is removed from the patient and sent through a machine that separates the plasma (the liquid part of the blood) from the blood cells. The patient's plasma contains the unneeded antibodies and is not returned to the patient. The normal blood cells are returned to the bloodstream along with donated plasma or a plasma replacement. Plasmapheresis does not keep new antibodies from forming.
Sources: circulation · plasmapheresis · plasma · donated
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change.
Sources: Watchful waiting · monitoring · condition
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Antibiotic therapy is a treatment that uses drugs to treat infections and cancer caused by bacteria and other microorganisms.
Sources: Antibiotic · infections · bacteria · microorganisms
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Surgery may be used to remove the lymphoma in certain patients with indolent or aggressive non-Hodgkin lymphoma.
Sources: Surgery · indolent · aggressive
The type of surgery used depends on where the lymphoma formed in the body:
Local excision for certain patients with mucosa-associated lymphoid tissue (MALT) lymphoma, PTLD, and small bowel T-cell lymphoma.
Sources: excision · mucosa-associated lymphoid tissue (MALT) lymphoma
Splenectomy for patients with marginal zone lymphoma of the spleen.
Sources: Splenectomy · marginal zone lymphoma · spleen
Patients who have a heart, lung, liver, kidney, or pancreas transplant usually need to take drugs to suppress their immune system for the rest of their lives. Long-term immunosuppression after an organ transplant can cause a certain type of non-Hodgkin lymphoma called posttransplant lymphoproliferative disorder (PLTD).
Sources: lung · liver · kidney · pancreas · transplant · immunosuppression · posttransplant lymphoproliferative disorder
Small bowel surgery is often needed to diagnose celiac disease in adults who develop a type of T-cell lymphoma.
Sources: bowel · diagnose · celiac disease
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Stem cell transplant is a method of giving high doses of chemotherapy and/or total-body irradiation and then replacing blood-forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient (autologous transplant) or a donor (allogeneic transplant) and are frozen and stored. After the chemotherapy and/or radiation therapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body’s blood cells.
Sources: doses · Stem cells · bone marrow · autologous transplant · donor · allogeneic transplant
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Vaccine therapy is a cancer treatment that uses a substance or group of substances to stimulate the immune system to find the tumor and kill it.
Sources: Vaccine therapy · tumor
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following:
Sources: indolent · stage I · contiguous · stage II · non-Hodgkin lymphoma
Radiation therapy.
Sources: Radiation therapy
Monoclonal antibody therapy (rituximab) and/or chemotherapy.
Sources: Monoclonal antibody · therapy · rituximab · chemotherapy
Watchful waiting.
Sources: Watchful waiting
If the tumor is too large to be treated with radiation therapy, the treatment options for indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma will be used.
Sources: tumor · noncontiguous · stage II · III · IV
Treatment of indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following:
Monoclonal antibody therapy (rituximab) with or without chemotherapy.
Lenalidomide and rituximab.
Sources: Lenalidomide
Maintenance therapy with rituximab.
Sources: Maintenance therapy
Monoclonal antibody therapy (obinutuzumab) with or without chemotherapy.
Sources: obinutuzumab
EZH2 inhibitor therapy (tazemetostat).
Sources: EZH2 · tazemetostat
Radiolabeled monoclonal antibody therapy.
Sources: Radiolabeled
A clinical trial of high-dose chemotherapy with or without total-body irradiation or radiolabeled monoclonal antibody therapy, followed by autologous or allogeneic stem cell transplant.
Sources: clinical trial · high-dose chemotherapy · total-body irradiation · autologous · allogeneic stem cell transplant
A clinical trial of chemotherapy with or without vaccine therapy.
Sources: vaccine therapy
A clinical trial of new types of monoclonal antibodies.
A clinical trial of radiation therapy that includes nearby lymph nodes, for patients who have stage III disease.
Sources: lymph nodes
A clinical trial of low-dose radiation therapy, to relieve symptoms and improve quality of life.
Sources: low-dose radiation therapy · quality of life
Other treatments for indolent non-Hodgkin lymphoma depend on the type of non-Hodgkin lymphoma. Treatment may include the following:
For follicular lymphoma, treatment may be within a clinical trial of new monoclonal antibody therapy, new chemotherapy regimen, or a stem cell transplant.
Sources: follicular lymphoma · regimen · stem cell transplant
For lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), tyrosine kinase inhibitor therapy and/or plasmapheresis or proteasome inhibitor therapy (if needed to make the blood thinner) is used. Other treatments that are like those used for follicular lymphoma may also be given.
Sources: lymphoplasmacytic lymphoma · tyrosine kinase inhibitor · plasmapheresis · proteasome inhibitor · blood
For gastric mucosa-associated lymphoid tissue (MALT) lymphoma, antibiotic therapy to treat Helicobacter pylori infection is given first. For tumors that do not respond to antibiotic therapy, treatment is radiation therapy, surgery, or rituximab with or without chemotherapy.
Sources: gastric · mucosa-associated lymphoid tissue (MALT) lymphoma · antibiotic · Helicobacter pylori · infection · respond · surgery
For extragastric MALT lymphoma of the eye and Mediterranean abdominal lymphoma, antibiotic therapy is used to treat infection.
For splenic marginal zone lymphoma, rituximab with or without chemotherapy and B-cell receptor therapy is used as initial treatment. If the tumor does not respond to treatment, a splenectomy may be done.
Sources: splenic · marginal zone lymphoma · splenectomy
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of aggressive stage I and aggressive, contiguous stage II non-Hodgkin lymphoma may include the following:
Sources: aggressive · stage I · contiguous · stage II · non-Hodgkin lymphoma
Monoclonal antibody therapy (rituximab) and combination chemotherapy. Sometimes radiation therapy is given later.
Sources: Monoclonal antibody · therapy · rituximab · combination chemotherapy · radiation therapy
A clinical trial of a new regimen of monoclonal antibody therapy and combination chemotherapy.
Sources: clinical trial · regimen
Treatment of aggressive, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following:
Sources: noncontiguous · stage II · III · IV
Monoclonal antibody therapy (rituximab) with combination chemotherapy.
Combination chemotherapy.
A clinical trial of monoclonal antibody therapy with combination chemotherapy followed by radiation therapy.
Other treatments depend on the type of aggressive non-Hodgkin lymphoma. Treatment may include the following:
For extranodal NK-/T-cell lymphoma, radiation therapy that may be given before, during, or after chemotherapy and CNS prophylaxis.
Sources: extranodal · NK · T-cell lymphoma · chemotherapy · CNS prophylaxis
For mantle cell lymphoma, monoclonal antibody therapy with combination chemotherapy, followed by stem cell transplant. Monoclonal antibody therapy may be given afterwards as maintenance therapy (treatment that is given after initial therapy to help keep cancer from coming back).
Sources: mantle cell lymphoma · stem cell transplant · maintenance therapy
For posttransplantation lymphoproliferative disorder, treatment with immunosuppressive drugs may be stopped. If this does not work or cannot be done, monoclonal antibody therapy alone or with chemotherapy may be given. For cancer that has not spread, surgery to remove the cancer or radiation therapy may be used.
Sources: posttransplantation lymphoproliferative disorder · immunosuppressive · drugs · cancer · surgery
For plasmablastic lymphoma, treatments are like those used for lymphoblastic lymphoma or Burkitt lymphoma.
Sources: plasmablastic lymphoma · lymphoblastic lymphoma · Burkitt lymphoma
For information on the treatment of lymphoblastic lymphoma, see Treatment Options for Lymphoblastic Lymphoma and for information on the treatment of Burkitt lymphoma, see Treatment Options for Burkitt Lymphoma.
Sources: Treatment Options for Lymphoblastic Lymphoma · Treatment Options for Burkitt Lymphoma
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of lymphoblastic lymphoma may include the following:
Sources: lymphoblastic lymphoma
Combination chemotherapy and CNS prophylaxis. Sometimes radiation therapy is also given to shrink a large tumor.
Sources: Combination chemotherapy · CNS prophylaxis · radiation therapy · tumor
Targeted therapy with a monoclonal antibody alone (rituximab) or combined with kinase inhibitor therapy (ibrutinib).
Sources: Targeted therapy · monoclonal antibody · rituximab · kinase inhibitor · therapy · ibrutinib
A clinical trial of stem cell transplant after initial treatment.
Sources: clinical trial · stem cell transplant
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of Burkitt lymphoma may include the following:
Sources: Burkitt lymphoma
Combination chemotherapy with or without monoclonal antibody therapy.
Sources: Combination chemotherapy · monoclonal antibody · therapy
CNS prophylaxis.
Sources: CNS prophylaxis
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of indolent, recurrent non-Hodgkin lymphoma may include the following:
Sources: indolent · recurrent · non-Hodgkin lymphoma
Monoclonal antibody therapy (rituximab or obinutuzumab) with or without chemotherapy.
Sources: Monoclonal antibody · therapy · rituximab · obinutuzumab · chemotherapy
Lenalidomide and rituximab.
Sources: Lenalidomide
EZH2 inhibitor therapy (tazemetostat).
Sources: EZH2 · tazemetostat
Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.
Sources: Radiation therapy · palliative therapy · symptoms · quality of life
Chemotherapy with one or more drugs.
Sources: Chemotherapy · drugs
Radiolabeled monoclonal antibody therapy.
Sources: Radiolabeled
CAR T-cell therapy.
Sources: CAR T-cell therapy
Bispecific monoclonal antibody therapy (mosunetuzumab).
Sources: Bispecific monoclonal antibody · mosunetuzumab
Stem cell transplant.
Sources: Stem cell transplant
Treatment of aggressive, recurrent non-Hodgkin lymphoma may include the following:
Sources: aggressive
CAR T-cell therapy with axicabtagene ciloleucel for primary refractory disease or relapse within 1 year.
Sources: CAR T-cell therapy · axicabtagene ciloleucel · primary · refractory · relapse
Bone marrow transplant or stem cell transplant consolidation therapy.
Sources: Bone marrow transplant · consolidation therapy
CAR T-cell therapy for relapse after autologous stem cell transplant.
Sources: autologous
Tafasitamab plus lenalidomide.
Sources: Tafasitamab
Rituximab plus lenalidomide.
Polatuzumab vedotin plus rituximab and bendamustine.
Sources: Polatuzumab vedotin · bendamustine
Loncastuximab tesirine.
Sources: Loncastuximab tesirine
Bispecific monoclonal antibody therapy (mosunetuzumab).
Chemotherapy with or without stem cell transplant.
Sources: stem cell transplant
For certain T-cell lymphomas, monoclonal antibody therapy with mogamulizumab.
Sources: T-cell lymphomas · mogamulizumab
Monoclonal antibody therapy with or without combination chemotherapy followed by autologous stem cell transplant.
Sources: combination chemotherapy
Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.
Radiolabeled monoclonal antibody therapy.
For mantle cell lymphoma, treatment may include the following:
Sources: mantle cell lymphoma
For mantle cell lymphoma, treatment may include the following:
Bruton tyrosine kinase inhibitor therapy.
Sources: tyrosine kinase inhibitor
Rituximab with or without a tyrosine kinase inhibitor (ibrutinib).
Sources: ibrutinib
Lenalidomide.
Sources: Lenalidomide
A clinical trial of lenalidomide with monoclonal antibody therapy.
A clinical trial comparing lenalidomide to other therapy.
A clinical trial of proteasome inhibitor therapy (bortezomib).
Sources: proteasome inhibitor · bortezomib
For diffuse large B-cell lymphoma, treatment may include the following:
Sources: diffuse large B-cell lymphoma
For diffuse large B-cell lymphoma, treatment may include the following:
Tafasitamab plus lenalidomide.
Polatuzumab vedotin, combined with bendamustine and rituximab.
A clinical trial of autologous or allogeneic stem cell transplant.
Treatment of indolent lymphoma that comes back as aggressive lymphoma depends on the type of non-Hodgkin lymphoma and may include radiation therapy as palliative therapy to relieve symptoms and improve quality of life. Treatment of aggressive lymphoma that comes back as indolent lymphoma may include chemotherapy.
Sources: indolent lymphoma · aggressive lymphoma
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Women who have indolent (slow-growing) non-Hodgkin lymphoma during pregnancy may be treated with watchful waiting until after they give birth. (See the Treatment Options for Indolent Non-Hodgkin Lymphoma section for more information.)
Sources: indolent · non-Hodgkin lymphoma · pregnancy · watchful waiting · Treatment Options for Indolent Non-Hodgkin Lymphoma
Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: August 22, 2024. Captured 2026-09-09.
Treatment of aggressive non-Hodgkin lymphoma during pregnancy may include the following:
Sources: aggressive · non-Hodgkin lymphoma · pregnancy
Treatment given right away based on the type of non-Hodgkin lymphoma to increase the mother's chance of survival. Treatment may include combination chemotherapy and rituximab.
Sources: survival · combination chemotherapy · rituximab
Early delivery of the baby followed by treatment based on the type of non-Hodgkin lymphoma.
If in the first trimester of pregnancy, medical oncologists may advise ending the pregnancy so that treatment may begin. Treatment depends on the type of non-Hodgkin lymphoma.
Sources: medical oncologists
Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma
ClinicalTrials.gov recordTumors Characterized by Genetic Abnormalities of ALK
ClinicalTrials.gov recordIndolent Non-Hodgkin's Lymphomas
ClinicalTrials.gov recordIndolent Non-Hodgkin's Lymphomas
ClinicalTrials.gov recordAnaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordWaldenström's Macroglobulinemia
ClinicalTrials.gov recordLymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
ClinicalTrials.gov recordMediastinal Large B-cell Lymphoma, Richter Syndrome
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma
ClinicalTrials.gov recordFollicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordGraft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid, Leukemia, Myelomonocytic, Chronic, Leukemia, Lymphocytic, Lymphoma, Lymphoma, Mantle-cell,...
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordHematologic Malignancies, Bone Marrow Transplant Rejection
ClinicalTrials.gov recordLeukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic, Myelodysplastic Syndromes, Multiple Myeloma, Lymphoma,...
ClinicalTrials.gov recordContiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin...
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordHodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
ClinicalTrials.gov recordLeukemia, Lymphoma
ClinicalTrials.gov recordLeukemia, Lymphoma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Multiple Myeloma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Multiple Myeloma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Multiple Myeloma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLeukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute
ClinicalTrials.gov recordMultiple Myeloma, Lymphoma, Non-Hodgkin's
ClinicalTrials.gov recordMultiple Myeloma, Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordHodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
ClinicalTrials.gov recordLeukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
ClinicalTrials.gov recordLeukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal...
ClinicalTrials.gov recordCardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
ClinicalTrials.gov recordCNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
ClinicalTrials.gov recordHodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
ClinicalTrials.gov recordLymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordT-cell Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordMultiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
ClinicalTrials.gov recordAIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma,...
ClinicalTrials.gov recordLymphoma, Non-Hodgkins
ClinicalTrials.gov recordLeukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Myeloma
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma, CNS Lymphoma
ClinicalTrials.gov recordB-Cell Lymphoma Originating in the CNS
ClinicalTrials.gov recordRecurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
ClinicalTrials.gov recordRecurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent...
ClinicalTrials.gov recordT-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
ClinicalTrials.gov recordChronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic...
ClinicalTrials.gov recordHepatosplenic T-Cell Lymphoma
ClinicalTrials.gov recordLymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
ClinicalTrials.gov recordPrimary Central Nervous System Non-Hodgkin Lymphoma
ClinicalTrials.gov recordLymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
ClinicalTrials.gov recordMultiple Myeloma, Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordMultiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
ClinicalTrials.gov recordCentral Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory...
ClinicalTrials.gov recordLymphoma, T-Cell, Peripheral
ClinicalTrials.gov recordLymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
ClinicalTrials.gov recordAIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi...
ClinicalTrials.gov recordHIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt...
ClinicalTrials.gov recordAdvanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
ClinicalTrials.gov recordAIDS-Related Primary Effusion Lymphoma
ClinicalTrials.gov recordLymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral
ClinicalTrials.gov recordAdult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma, Ann Arbor Stage...
ClinicalTrials.gov recordNon Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic...
ClinicalTrials.gov recordMarginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma
ClinicalTrials.gov recordT Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
ClinicalTrials.gov recordAnaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma,...
ClinicalTrials.gov recordBreast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Ovary Cancer, Prostate Cancer, Thyroid Cancer, Non-Hodgkin Lymphoma
ClinicalTrials.gov recordRecurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell...
ClinicalTrials.gov recordRefractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
ClinicalTrials.gov recordMultiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
ClinicalTrials.gov recordMultiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, HDT-AHCT
ClinicalTrials.gov recordEpstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD,...
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Hodgkin Disease
ClinicalTrials.gov recordHigh Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Non-Hodgkin Lymphoma
Non-Hodgkin lymphomas may be grouped for treatment according to whether the cancer is indolent or aggressive, whether affected lymph nodes are next to each other in the body, and whether the cancer is newly diagnosed or recurrent.
Treatment of Recurrent Non-Hodgkin Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
1.1 Non-Hodgkin's Lymphoma (NHL) RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
1.1 Non–Hodgkin's Lymphoma (NHL) RITUXAN is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
• Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. o Previously untreated follicular, CD20-positive, B-cell NHL in combination with...
Small Intestinal Lymphoma
1.1 Non–Hodgkin's Lymphoma (NHL) TRUXIMA (rituximab-abbs) is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
1.1 Relapsed or Refractory, Low-grade or Follicular NHL Zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).
1 INDICATIONS AND USAGE Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular...
For the treatment of relapsed follicular B-cell Non-Hodgkin Lymphoma (FL) in patients who have received at least 2 prior systemic therapies and relapsed small lymphocytic lymphoma (SLL) in patients who have received at least 2 prior...
JYLAMVO is a folate analog metabolic inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults...
DailyMed labelZevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's...
DailyMed label